YU89103A - Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a - Google Patents

Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a

Info

Publication number
YU89103A
YU89103A YU89103A YUP89103A YU89103A YU 89103 A YU89103 A YU 89103A YU 89103 A YU89103 A YU 89103A YU P89103 A YUP89103 A YU P89103A YU 89103 A YU89103 A YU 89103A
Authority
YU
Yugoslavia
Prior art keywords
ocd
obsessive
related disorders
compulsive disorder
gvg
Prior art date
Application number
YU89103A
Other languages
English (en)
Inventor
Stephen L. Dewey
Jonathan D. Brodie
Charles R. Ashby Jr.
Original Assignee
Brookhaven Science Associates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Associates filed Critical Brookhaven Science Associates
Publication of YU89103A publication Critical patent/YU89103A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Predmetni pronalazak se odnosi na korišćenje γ-vinil GABA (GVG) i drugih GABA-ergičkih sredstava u lečenju opsesivno - kompulsivnog poremećaja (OKP) i poremećaja koji su povezani sa OKP, kao i za smanjenje ili otklanjanje ponašanja koja su udružena sa opsesivno - kompulsivnim poremećajem (OKP) i sa poremećajima koji su povezani sa (OKP).[The present invention relates to the use of gamma vinyl-GABA (GVG) and other GABAergic agents to treat obsessive-compulsive disorder (OCD) and OCD-related disorders, and to reduce or eliminate behaviors associated with obsessive-compulsive disorder (OCD) and OCD-related disorders.
YU89103A 2001-05-14 2002-05-08 Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a YU89103A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/853,392 US6462084B1 (en) 2001-05-14 2001-05-14 Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG

Publications (1)

Publication Number Publication Date
YU89103A true YU89103A (sh) 2006-08-17

Family

ID=25315916

Family Applications (1)

Application Number Title Priority Date Filing Date
YU89103A YU89103A (sh) 2001-05-14 2002-05-08 Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a

Country Status (18)

Country Link
US (2) US6462084B1 (sh)
EP (1) EP1392273A4 (sh)
JP (1) JP2004533445A (sh)
KR (1) KR20040028758A (sh)
CN (1) CN1509168A (sh)
BR (1) BR0209614A (sh)
CA (1) CA2446641A1 (sh)
CZ (1) CZ20033379A3 (sh)
HR (1) HRP20030894A2 (sh)
HU (1) HUP0400032A3 (sh)
IL (1) IL158761A0 (sh)
MX (1) MXPA03010406A (sh)
NO (1) NO20035037L (sh)
NZ (1) NZ529613A (sh)
PL (1) PL367362A1 (sh)
TW (1) TWI313599B (sh)
WO (1) WO2002092071A1 (sh)
YU (1) YU89103A (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
PL375090A1 (en) * 2002-06-27 2005-11-14 Warner-Lambert Company Llc Method of treating attention deficit hyperactivity disorder
JP2007526212A (ja) * 2003-04-25 2007-09-13 アラーガン、インコーポレイテッド 種々の障害を軽減するためのボツリヌス神経毒の使用
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2011106692A2 (en) * 2010-02-25 2011-09-01 Northwestern University Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3003297A4 (en) * 2013-06-05 2017-04-19 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN104306736A (zh) * 2014-10-31 2015-01-28 哈尔滨市海江科技开发有限公司 一种治疗疑病症的膏药及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761429A (en) 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US4786647A (en) 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US4980168A (en) 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
EP0767174A1 (de) 1991-11-21 1997-04-09 Ciba-Geigy Ag Neue Aminoalkanphosphinsäuren und ihre Salze
CA2134674C (en) * 1992-05-20 2004-12-21 Richard B. Silverman Gaba and l-glutamic acid analogs for antiseizure treatment
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
CA2258893C (en) 1996-06-28 2005-06-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5776956A (en) 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
EP1043980A2 (en) 1997-10-28 2000-10-18 Schering Corporation Method of reducing craving in mammals
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
AU759756B2 (en) * 1998-10-20 2003-05-01 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse
IL144407A0 (en) 1999-02-01 2002-05-23 Ortho Mcneil Pharm Inc Use of anticonvulsant derivatives for treating bulimia nervosa
AU779248B2 (en) 1999-02-24 2005-01-13 University Of Cincinnati, The Use of sulfamate derivatives for treating impulse control disorders
JP2003530300A (ja) 1999-04-08 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 体重低下を維持することに有用な抗痙攣薬誘導体
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Also Published As

Publication number Publication date
US6462084B1 (en) 2002-10-08
TWI313599B (en) 2009-08-21
MXPA03010406A (es) 2004-05-05
WO2002092071A1 (en) 2002-11-21
EP1392273A4 (en) 2004-11-24
CA2446641A1 (en) 2002-11-21
NZ529613A (en) 2006-09-29
EP1392273A1 (en) 2004-03-03
HRP20030894A2 (en) 2004-06-30
JP2004533445A (ja) 2004-11-04
KR20040028758A (ko) 2004-04-03
NO20035037L (no) 2004-01-07
IL158761A0 (en) 2004-05-12
HUP0400032A2 (hu) 2004-04-28
PL367362A1 (en) 2005-02-21
CN1509168A (zh) 2004-06-30
HUP0400032A3 (en) 2012-09-28
US20020169103A1 (en) 2002-11-14
NO20035037D0 (no) 2003-11-13
CZ20033379A3 (cs) 2004-12-15
BR0209614A (pt) 2004-12-07

Similar Documents

Publication Publication Date Title
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
RS20060320A (en) Substituted indazole-o-glucosides
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
SG130189A1 (en) Substituted indole-o-glucosides
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
UA87991C2 (en) Substituted indole-o-glucosides
WO2003101397A3 (en) Tetravalent dengue vaccines
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
MXPA03010327A (es) USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
AU1171102A (en) Uridine therapy for patients with elevated purine levels
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
GB9924941D0 (en) Treatment of dyskinesia
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
EP1430025A4 (en) METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING BACTERIAL INFECTIONS
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
UA85187C2 (en) 2-aminobenzoyl derivatives
MXPA04000008A (es) Carbamatos de 2-heterociclic-1,2-etanodioles.
HK1056120A1 (en) Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder.